Previous Close | 9.58 |
Open | 9.58 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 9.58 - 9.58 |
52 Week Range | 7.77 - 18.79 |
Volume | |
Avg. Volume | 703 |
Market Cap | 4.36B |
Beta (5Y Monthly) | 0.70 |
PE Ratio (TTM) | 11.97 |
EPS (TTM) | 0.80 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.17 (1.81%) |
Ex-Dividend Date | Sep 22, 2021 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for APNHY
Africa's top public health body said on Thursday it was hopeful South African pharmaceutical firm Aspen Pharmacare would get orders for its own brand COVID-19 vaccine. Africa Centers for Disease Control and Prevention (CDC) said last month that it is in detailed discussions with buyers to generate demand for Aspen's COVID-19 vaccine Aspenovax. Just one fifth of adults in Africa are fully vaccinated against COVID-19, but demand has fallen across the continent which already receives donated vaccines from Western countries and has supplies to hand from earlier purchases.
South Africa's Aspen Pharmacare's COVID-19 vaccine production lines may soon go idle, and without any new orders it could be forced to pivot to manufacturing other products, a senior executive said on Wednesday. Aspen currently produces vaccines for Johnson & Johnson and, in March, it struck a deal to produce, price, and sell its own-brand version of the shot for African markets. Aspen has had no orders for its Aspenovax vaccine, and it is not possible to predict future J&J demand, Stavros Nicolaou, Aspen Group Senior Executive, told Reuters, leaving the future of its 450-million-dose annual production capacity in doubt.
South Africa's Aspen Pharmacare will stop making COVID-19 vaccines from the end of this month due to a lack of orders, a senior executive said, further undermining Africa's already meager capacity to produce doses. Aspen currently produces vaccines for Johnson & Johnson .